

## Workshop

14:00–17:30

**Social Medical Implication of Chronic Fatigue in HL**HEXAL **InterContinental Hotel | Room: Pfau**

Participation by Invitation Only. WS Language German.

**Workshops** InterContinental Hotel

## Workshop 1 (parallel sessions)

14:00–15:30

**HL in Adolescents: a Controversy?** **Room: Severin**

Joseph Connors (Vancouver/CDN), Dieter Körholz (Halle/D)

An Oxford Style Debate on the Statement: "Adolescents and Young Adults with HL Should Be Treated According to Pediatric HL Protocols"

<b>Pro</b>	Treatment of Hodgkin Lymphoma: Comparison of Treatment Intensity and Efficacy of Pediatric and Adult Protocols	Christine Mauz-Körholz (Halle/D)
------------	--	----------------------------------

	Hodgkin Lymphoma in Adolescents: French Experience and Conclusions	Judith Landman-Parker (Paris/F)
--	--	---------------------------------

<b>Contra</b>	Adolescents Are Biological Adults	Joseph Connors (Vancouver/CDN)
---------------	-----------------------------------	--------------------------------

	Hodgkin Lymphoma in Adolescents and Young Adults Is Best Managed as an Adult Disease	Peter Borchmann (Cologne/D)
--	--	-----------------------------

## Workshop 2 (parallel sessions)

14:00–15:30

**Interim PET in HL** **Room: Pipin II**

Andrea Gallamini (Cuneo/I), Aaron Polliack (Jerusalem/IL)

Towards Standardization of Scanning and Reporting of Results	Michael O'Doherty (London/UK)
--	-------------------------------

Logistics of the Network of Imaging Exchange and the Review Panel	Michel Meignan (Creteil/F)
---	----------------------------

Interim PET and the Role of Radiotherapy in Early Stage Disease	Tim Illidge (Manchester/UK)
---	-----------------------------

Interim-PET in Tailoring Therapy in Early Stage HL – The EORTC-GELA-III Experience	Elly Lugtenburg (Rotterdam/NL)
--	--------------------------------

Interim-PET in the Therapeutic Strategy of Advanced Stage HL	Martin Hutchings (Copenhagen/DK)
--	----------------------------------

Interim-PET in Patients with Advanced HL Treated with Non-ABVD Regimens	Abraham Avigdor (Tel Hashomer/IL)
---	-----------------------------------

Interim-PET During BEACOPP Chemotherapy: Experience of the GHSG	Markus Dietlein (Cologne/D)
---	-----------------------------

## Workshop 3 (parallel sessions)

14:00–15:30

**Basic Research** **Room: Pipin I**

Ralf Küppers (Essen/D), Anke van den Berg (Groningen/NL)

Molecular Cytogenetic Studies in Hodgkin Lymphoma	Reiner Siebert (Kiel/D)
---	-------------------------

The role of KLF4 and FoxO1 in Hodgkin Lymphoma	Thomas Wirth (Ulm/D)
--	----------------------

JAK2 Rearrangements, Including the Novel SEC31A-JAK2 Fusion, Are Recurrent in Classical Hodgkin Lymphoma	Iwona Wlodarska (Leuven/B)
--	----------------------------

HLA Expression and Genetic Associations in EBV Positive and EBV Negative Classical Hodgkin Lymphoma	Anke van den Berg (Groningen/NL)
---	----------------------------------

Immune Escape in Hodgkin Lymphoma and PTLD – the Role and Targeting of Galectin-1	Margaret Shipp (Boston/USA)
---	-----------------------------

**Workshop 4** (parallel sessions) **14:00–15:30****Follow-Up in Long Term Survivors: Recommendations**

Room: Martin &amp; Augustin

John Raemaekers (Nijmegen/NL), Joachim Yahalom (New York/USA)

Epidemiology Trends of HL in Sweden	Magnus Björkholm (Stockholm/S)
Breast Cancer	Flora van Leeuwen (Amsterdam/NL)
Lung Cancer	John Radford (Manchester/UK)
Cardiovascular Screening	Sandy Constine (Rochester/USA)

**Workshop 5** (parallel sessions) **16:00–17:30****HL Pathologists' Meeting** Room: Sandkaul

Randy Gascoyne (Vancouver/CDN), Harald Stein (Berlin/D)

Methylation Profiling of Mediastinal Gray Zone Lymphoma	Franziska Eberle (Bethesda/USA)
DNA Methylation Analyses in Hodgkin Lymphoma	Reiner Siebert (Kiel/D)
Mechanisms of Aberrant GATA-3 Expression in Classical Hodgkin Lymphoma	Jens Stanelle (Essen/D)
Genome-Wide Copy Number Analysis of Microdissected HRS Cells in Classical Hodgkin Lymphoma	Christian Steidl (Vancouver/CDN)

**Workshop 6** (parallel sessions) **16:00–17:30****NLPHL: Treatment Recommendations** Room: Martin & Augustin

Michele Ghilmini (Bellinzona/CH), Andrew Lister (London/UK)

The Optimal First Line treatment	Ranjana Advani (Stanford/USA)
Options in Subsequent Relapses	Dennis Eichenauer (Cologne/D)
Radiotherapy Alone is Sufficient in Early Stage	Andrew Wirth (Melbourne/AUS)
Chemotherapy Should Be Added to Radiotherapy in Early Stage	Joseph Connors (Vancouver/CDN)

**Workshop 7** (parallel sessions) **16:00–17:30****Defining RT Field and Dose** Room: Pipin I

Theodore Girinsky (Villejuif/F), Lena Specht (Copenhagen/DK)

Evidence for Radiotherapy in Early Stage Hodgkin Lymphoma, Volume and Dose – Review of the Meta-Analyses	Lena Specht (Copenhagen/DK)
Evidence for Radiotherapy in Advanced Stage Hodgkin Lymphoma, Volume and Dose	Berthe Aleman (Amsterdam/NL)
RT Dose in Early Stages – the GHSG Studies	Michael Fuchs (Cologne/D)
Reductions in Irradiated Volume in Hodgkin Lymphoma, IFRT and INRT	Theodore Girinsky (Villejuif/F)
Is INRT Suitable for Pediatric Patients?	Sandy Constine (Rochester/USA)
Highly Conformal Radiotherapy for Hodgkin Lymphoma, IMRT, Arc Therapy, Proton Therapy	Brad Hoppe (Jacksonville/USA)
Imaging for Highly Conformal Radiotherapy for Hodgkin Lymphoma	Stephanie Terezakis (Baltimore/USA)
Uncertainties in Highly Conformal Radiotherapy for Hodgkin Lymphoma	Lena Specht (Copenhagen/DK)
Panel Discussion and Proposal for an 'International Forum for Lymphoma Radiation Oncologists'	Joachim Yahalom (New York/USA)

**Workshop 8** (parallel sessions) **16:00–17:30****HL in Non-Western Countries** Room: Severin

James Armitage (Omaha/USA), Andreas Engert (Cologne/D)

Hodgkin Lymphoma in Non-Western Countries: Pathology Elaine Jaffe (Bethesda/USA)

Hodgkin Lymphoma in Non-Western Countries: Africa Peter Jacobs (Johannesburg/RSA)

Hodgkin Lymphoma in Non-Western Countries: South America Carlos Chiattono (Sao Paulo/BR)

Hodgkin Lymphoma in Non-Western Countries: Middle East Hamdy Abdel Azim (Kairo/ET)

Hodgkin Lymphoma in Non-Western Countries: China Wenqi Jiang (Guangzhou/CHN)

**Workshop 9** (parallel sessions) **16:00–17:30**  
**(By Invitation Only)****Lymphoma Response Evaluation** Room: Pipin II

Bruce Cheson (Washington/USA), Anas Younes (Houston/USA)

Response Assessment in Clinical Practice and Clinical Research Anas Younes (Houston/USA)

Experience with PET in Hodgkin Lymphoma Martin Hutchings (Copenhagen/DK)

Current Risk Adapted Clinical Trials in Hodgkin Lymphoma John Radford (Manchester/UK)

Recent Modifications of the International Response Criteria for Lymphoma Bruce Cheson (Washington/USA)

New Directions in Imaging for Lymphoma Lale Kostakoglu (New York/USA)

**Sunday, 24.10.2010****Patiententag****An Interactive Survivor Symposium** Gürzenich, Kleiner Saal  
**with Focus on Quality of Life** **09:00–12:15****Scientific Session 1** **09:30–10:30****The HL Stem Cell** Gürzenich, Großer Saal

Bernd Dörken (Berlin/D), Randy Gascoyne (Vancouver/CDN)

Leukaemic Stem Cells: AML Show the Way Dominique Bonnet (London/UK)

Cancer Stem Cells in Hodgkin Lymphoma Richard Ambinder (Baltimore/USA)

Aspects of the Relationship of Hodgkin and Reed/Sternberg Cells and Potential Precursor Cells Ralf Küppers (Essen/D)

**Scientific Session 2** **10:30–12:00****Lymphoma Microenvironment** Gürzenich, Großer Saal

Margaret Shipp (Boston/USA), Harald Stein (Berlin/D)

Classical Hodgkin Lymphoma Micro-environment. Pathologic Aspects and the Role of CD40 / CD40L Antonino Carbone (Milan/I)

Gene and Micro-RNAs Signatures as Predictors of Risk in Hodgkin Lymphoma: Integrating Tumor and Microenvironment Juan Fernando Garcia (Madrid/E)

Can Immunohistochemical Markers at Diagnosis Have the Same Predictive Value of Early Interim-PET in Classical Hodgkin Lymphoma? Stefano Pileri (Bologna/I)

Integrative Analysis Reveals Selective 9p24.1 Amplification, Increased PD-L1 Ligand Expression and Further Induction via JAK2 in Nodular Sclerosing Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma Margaret Shipp (Boston/USA)

## Lunch Symposium (Celgene GmbH) 12:15–13:30

### Lenalidomide in Lymphoma – Latest Update on Clinical Data

Gürzenich, Großer Saal

Volker Diehl (Cologne/D)

12:15–12:40

Rational and Clinical Experiences with Lenalidomide in Hodgkin Lymphoma

Boris Böll (Cologne/D)

12:40–13:05

Progress in CLL Treatment

Clemens-Martin Wendtner (Cologne/D)

13:05–13:30

Emerging Treatment Options for Mantle Cell Lymphoma

Marek Trněný (Prague/CZ)

## Satellite Symposium (Millennium: The Takeda Oncology Company) 14:00–15:00

### CD30 as a Target for Hodgkin Lymphoma

Gürzenich, Großer Saal

Andreas Engert (Cologne/D)

14:00

Welcome and Introduction

Andreas Engert (Cologne/D)

14:00–14:15

Clinical Gaps in the Treatment of Patients with Relapsed/Refractory Hodgkin Lymphoma

Peter Johnson (Southampton/UK)

14:15–14:30

Targeting CD30 in Hodgkin Lymphoma

Andreas Engert (Cologne/D)

14:30–14:45

Ongoing Phase III Trials in Relapsed/Refractory Hodgkin Lymphoma

Pauline Brice (Paris/F)

14:45–15:00

Panel Discussion: Optimizing the Path to Transplant for Patients with Late-Stage Hodgkin Lymphoma

Peter Johnson (Southampton/UK)  
Pauline Brice (Paris/F)  
Andreas Engert (Cologne/D)

## Satellite Symposium (Novartis Oncology) 16:00–17:30

### Novel Approaches in the Treatment of Hodgkin Lymphoma: Beyond Chemotherapy

Andreas Engert, (Cologne/D)

Gürzenich, Großer Saal

16:00–16:05

Welcome and Introduction

Andreas Engert, (Cologne/D)

16:05–16:25

DAC Inhibitors, a New Class of Compounds: Landscape and MOA

Anas Younes (Houston/USA)

16:25–16:45

Evolution of Panobinostat in Treating Hodgkin Lymphoma

Franck Morschhauser (Lille/F)

16:45–17:05

Novartis Pipeline: Investigational Compounds in Lymphoma

Patrick Johnston (Rochester/USA)

17:05–17:25

New Products (LBH)

Anas Younes (Houston/USA)

17:25–17:30

Summary and Close

Andreas Engert, (Cologne/D)

## Opening Ceremony

Gürzenich Congress Center | 18:00–20:00

### Bonadonna Lecture

Gürzenich, Großer Saal

The Role of Viral Infections in Hodgkin Lymphoma

Harald zur Hausen (Heidelberg/D)

### Awards Ceremony

Gürzenich, Großer Saal

## Get Together

Gürzenich Congress Center | 20:00

Gürzenich, Basement

## Session 3

08:30–10:00

Basic Research **Gürzenich, Großer Saal**

Andreas Rosenwald (Würzburg/D), Margaret Shipp (Boston/USA)

## 08:30–08:50

Pathogenesis of HL

Ralf Küppers (Essen/D)

## 08:50–09:10

cHL and Microenvironment

Randy Gascoyne  
(Vancouver/CDN)

## 09:10–09:30

Rationale for Non-Genotoxic Treatment

Stephan Mathas (Berlin/D)

## 09:30–09:40 | C001

From High Dimensional Data to Disease  
Mechanisms – NOTCH Signaling in Hodgkin  
Lymphoma

Karl Köchert (Berlin/D)

## 09:40–09:50 | C002

The Role of miRNAs in Hodgkin Lymphoma

Anke van den Berg  
(Groningen/NL)

## 09:50–10:00 | C003

Methylation Profiling of Mediastinal Gray  
Zone Lymphoma Reveals a Distinctive  
Signature with Elements Shared by Classical  
Hodgkin Lymphoma and Primary Mediastinal  
Large B-Cell LymphomaFranziska Eberle  
(Bethesda/USA)

## Session 4

10:30–12:00

Early Stages **Gürzenich, Großer Saal**

Anton Hagenbeek (Amsterdam/NL), Richard Hoppe (Stanford/USA)

## 10:30–10:40 | Presentation

Actions Following the Interim Analysis of  
the EORTC/GELA/IL Intergrup H10 TrialJohn Raemaekers  
(Nijmegen/NL)

## 10:40–11:20

Debate: Role of Radiotherapy in Early  
Favorable HLAnton Hagenbeek  
(Amsterdam/NL)**Discussants:**George Canellos  
(Boston/USA),  
Joachim Yahalom  
(New York/USA)

## 11:20–11:40

State of the Art and Future Perspectives

Andreas Engert (Cologne/D)

## 11:40–11:50 | C046

Early FDG–PET Scan Confirms Its Prognostic  
Impact Also in Localized Stage, ABVD Treated  
Hodgkin Lymphoma Patients

Luigi Rigacci (Florence/I)

## 11:50–12:00 | C047

Involved Node Radiotherapy Significantly  
Reduces Lung, Breast and Thyroid Dose  
in Patients with Limited Stage Hodgkin  
LymphomaBelinda Campbell  
(Melbourne/AUS)

## Workshop 10 (parallel sessions)

10:30–12:00

Pediatric HL **Gürzenich, Grillrestaurant**

Cindy Schwartz (Providence/USA), Judith Landman–Parker (Paris/F)

Early Response–Based HL Therapies of the COG

Cindy Schwartz  
(Providence/USA)

Update on EuroNet–PHL–C1 trial

Dieter Körholz (Halle/D)

Hodgkin Lymphoma therapy in Central  
AmericaPedro de Alarcon  
(Peoria/USA)Involved Level 3–D Based Target Volume  
Concepts for Pediatric Hodgkin LymphomaLütgendorf–Caucig  
(Vienna/A)

Update on LPHL

Judith Landman–Parker  
(Paris/F)

## Panel Discussion

Cindy Schwartz (Providence/USA), Dieter Körholz (Halle/D),  
Judith Landman–Parker (Paris/F), Sandy Constine (Rochester/USA)

## Lunch Symposium (Roche Pharma AG)

12:00–14:00

### State-of-the-Art and Future Approaches

Michael Hallek (Cologne/D), Andreas Engert (Cologne/D) **Gürzenich, Großer Saal**

12:00–12:30 Lunch

12:30–12:55

Hodgkin Lymphoma

Peter Borchmann  
(Cologne/D)

12:55–13:20

Chronic Lymphatic Leukemia

Michael Hallek (Cologne/D)

13:20–14:00

Follicular Lymphoma

Gilles Salles (Lyon/F)

## Session 5

14:00–15:30

### Special Challenges in HL **Gürzenich, Großer Saal**

Magnus Björkholm (Stockholm/S), Teodoro Chisesi (Venice/I)

14:00–14:20

WS Report on Non-Western Countries

James Armitage  
(Omaha/USA)

14:20–14:40

WS Report on HL Treatment of Adolescents

Joseph Connors  
(Vancouver/CDN)

14:40–15:00

WS Report on NLPHL

Michele Ghielmini  
(Bellinzona/CH)

15:00–15:10 | C060

Hodgkin Lymphoma and HIV Infection (HD-HIV): Prognostic Factors in 596 Patients (Pts) within the European Group for the Study of HIV and Tumours

Michele Spina (Aviano/I)

15:10–15:20 | C131

Feasibility and Efficacy of ABVD in Elderly Hodgkin Lymphoma Patients: Analysis of Two Randomized Prospective Multicenter Trials of the German Hodgkin Study Group (HD10 and HD11)

Boris Böll  
(Cologne/Germany)

15:20–15:30 | C086

Autologous Stem Cell Transplantation for Adolescents and Young Adults with Relapsed or Refractory Hodgkin Lymphoma

Michael Crump  
(Toronto/CDN)

## Session 6

16:00–17:30

### Survivorship **Gürzenich, Großer Saal**

Franco Cavalli (Bellinzona/CH), Volker Diehl (Cologne/D)

16:00–16:20

WS Report on Follow-Up Recommendations

John Raemaekers  
(Nijmegen/NL)

16:20–16:40

Long-Term Outcome of Children and Adolescents

Kara Kelly (New York/USA)

16:40–17:00

Quality of Life in HL

Peter Borchmann  
(Cologne/D)

17:00–17:10 | C111

A Comprehensive Prospective National Database to Enhance Breast Cancer (BC) Screening Services for Hodgkin Lymphoma (HL) Survivors Treated with Supradiaphragmatic Radiotherapy (SRT) in England

Sacha Howell  
(Manchester/UK)

17:10–17:20 | C112

A Prospective Study of Breast Magnetic Resonance Imaging (MRI) and Mammographic Screening in Long-Term Female Hodgkin Lymphoma (HL) Survivors

Andrea Ng (Boston/USA)

17:20–17:30 | C113

Coronary Artery Disease in Patients Treated for Hodgkin Lymphoma: Preliminary Results Using Computed Angiography Tomography

Theodore Girinsky  
(Villejuif/F)

## Dinner Symposium

18:00–19:00

### (Ortho Biotech Division of Janssen-Cilag GmbH)

#### New Aspects of Lymphoma Therapy

Peter Borchmann (Cologne/D), Robert Marcus (Cambridge/UK)

**Gürzenich, Großer Saal**

Mantle Cell Lymphoma – Quo Vadis?

Georg Heß (Mainz/D)

Follicular Lymphoma – Bortezomib in the Relapsed/Refractory Setting

Mathias Rummel  
(Gießen/D)

## Session 7

08:30–10:00

**Transplantation** **Gürzenich, Großer Saal**

Christian Gisselbrecht (Paris/F), Norbert Schmitz (Hamburg/D)

**08:30–08:50**

Randomized Trials

Norbert Schmitz  
(Hamburg/D)**08:50–09:10**

Role of allo-TX

Anna Sureda (Barcelona/E)

**09:10–09:30**

Double APBSCT

Franck Morschhauser  
(Villejuif/F)**09:30–09:40 | C087**

Long Term Outcome of High-Dose Salvage Therapy for Patients with Early Stage Hodgkin Lymphoma (HL) Who Failed Initial Treatment with Combined Modality Treatment or Chemotherapy Alone

Andreas Rimner  
(New York/USA)**09:40–09:50 | C088**

Relapse of Hodgkin Lymphoma after Autologous Stem Cell Transplantation (ASCT): Identification of Prognostic Factors Predicting Outcome

Carmen Martinez  
(Barcelona/E)**09:50–10:00 | C089**

Allogeneic Stem Cell Transplantation for Hodgkin Lymphoma: a Retrospective Analysis of Data from the German Stem cell Transplantation Registry (DRST)

Christof Scheid (Cologne/D)

## Session 8

10:30–12:00

**New drugs** **Gürzenich, Großer Saal**

Peter Johnson (Southampton/UK), Anas Younes (Houston/USA)

**10:30–10:45**

SGN-35

Robert Chen (Duarte/USA)

**10:45–11:00**

LBH-589

Anas Younes (Houston/USA)

**11:00–11:15**

Everolimus for Relapsed/Refractory HL

Patrick Johnston  
(Rochester/USA)**11:15–11:30**

Lenalidomide

Nancy Bartlett  
(St. Louis/Washington)**11:30–11:45 | C090**Extended Follow-Up of the Safety of <sup>131</sup>I Radiolabelled Anti-CD25 Antibody, Basiliximab, in Patients with CD25-Positive, Refractory Hodgkin LymphomaNeha Bhatnagar  
(London/UK)**11:45–12:00 | C091**

Initial Results from the SAPHIRE Study: a Phase II Trial with the Novel Oral Histone Deacetylase (HDAC) Inhibitor Resminostat in Relapsed or Refractory Hodgkin Lymphoma Patients

Jan Walewski (Warsaw/PL)

**Lunch Symposium  
(Genzyme GmbH)**

12:15–13:15


**New Mobilisation Strategies in  
Autologous Stem Cell Transplantation**Norbert Schmitz (Hamburg/D) **Gürzenich, Großer Saal**

The Role and Challenges of Autologous Transplantation in Hodgkin Lymphoma

Karl Peggs (London/UK)

Optimizing Stem Cell Mobilization with Plerixafor in Hodgkin Lymphoma

Peter Dreger (Heidelberg/D)



## Posterwalk **Gürzenich, Kleiner Saal** 13:15–14:00

Please join the poster presentation and take the chance to discuss the results with our colleagues.

## Session 9 14:00–15:30

### PET **Gürzenich, Großer Saal**

Markus Dietlein (Cologne/D), Aaron Polliack (Tel Aviv/IL)

#### 14:00–14:20

PET for lymphoma Staging

Bruce Cheson  
(Washington/USA)

#### 14:20–14:40

Interim PET

Andrea Gallamini (Cuneo/I)

#### 14:40–15:00

PET during Follow-Up

Martin Hutchings  
(Copenhagen/DK)

#### 15:00–15:10 | C048

Contribution of PET/CT in the Design of the Involved Node Radiotherapy (INRT) Concept for Patients with Localized Hodgkin Lymphoma: Preliminary Results on 117 Patients entered in the H10 Trial

Theodore Girinsky  
(Villejuif/F)

#### 15:10–15:20 | C061

Early Interim FDG–PET during Intensified BEACOPP Therapy for Advanced–Stage Hodgkin Lymphoma Shows a Lower Positive Predictive Value than during ABVD

Francesca Fiore (Cuneo/I)

#### 15:20–15:30 | C132

A Bone Marrow Biopsy is Not Necessary in the Staging of Hodgkin Lymphoma (HL) Patients in the FDG–PET Era

Simon Richardson  
(London/UK)

## Session 10

16:00–17:30

### Advanced Stage **Gürzenich, Großer Saal**

George Canellos (Boston/USA), Patrice Carde (Villejuif/F)

#### 16:00–16:20

Update on Stanford V

Ranjana Advani  
(Stanford/USA)

#### 16:20–17:00

Debate: Kairos or Chronos? Early versus Late Intensification in Advanced HL

Patrice Carde (Villejuif/F)

#### Discussants:

Richard Fisher  
(Rochester/USA),  
Volker Diehl (Cologne/D)

#### 17:00–17:10

HD15–PET: Final Analysis

Andreas Engert (Cologne/D)

#### 17:10–17:20 | C062

Intensified ABVD for Newly Diagnosed Patients with Advanced–Stage Classical Hodgkin Lymphoma

Filippo Russo (Naples/I)

#### 17:20–17:30 | C063

BEACOPP is Superior to ABVD in Patients with Advanced Hodgkin Lymphoma and High Tumor Burden

Paolo Gobbi (Pavia/I)

## Closing Remarks

17:30

Andreas Engert (Cologne/D) **Gürzenich, Großer Saal**